The Latest Breaking News from FDA

Biden uses Defense Production Act to tackle US baby formula crisis

Government aims to speed production after closure of Abbott plant, as experts urge parents not to concoct own alternatives

The Guardian - US · May 19, 2022

FDA: Infant formula supply will increase quickly - Roll Call

The Biden administration says it will be 'a few weeks' before the baby food supply around the country is back to normal

Roll Call · May 19, 2022

Mid-Day Market Update: Nasdaq Rises 100 Points; Cisco Shares Plunge

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite adding 100 points on Thursday.

Benzinga · May 19, 2022

New COVID-19 mystery: Some are getting coronavirus again even after taking Paxlovid

Some coronavirus-positive patients who have completed treatment of the anti-COVID drug Paxlovid are rebounding into illness, and experts are urging people to be cautious if they develop COVID-like symptoms again and become infectious.

Los Angeles Times · May 19, 2022

Republicans vote "no" on baby food hike

Nine Republicans vote "no" on bill that would help low-income parents access baby food amid shortage

Salon · May 19, 2022

Mid-Morning Market Update: Markets Open Lower; US Jobless Claims Increase To 218,000

U.S. stocks traded lower this morning, with the Dow Jones dipping more than 300 points on Thursday.

Benzinga · May 19, 2022

Why NeuroMetrix Shares Are Skyrocketing

NeuroMetrix Inc (NASDAQ: NURO) shares are trading higher by 30.10% at $4.06 after the company announced the FDA has granted De Novo authorization to market the Quell neuromodulation device as an aid for reducing the symptoms of fibromyalgia.

Benzinga · May 19, 2022

FDA faces congressional scrutiny over baby formula shortage

The head of the Food and Drug Administration is facing congressional lawmakers for the first time over the national shortage of baby formula

The Independent UK · May 19, 2022

Baby formula industry was primed for disaster long before key factory closed down

The conditions that led to a shortage of baby formula were set in motion long before the February 2022 closure of the Similac factory tipped the U.S. into a crisis.

The Conversation · May 19, 2022

Mersana Stock Gains On FDA Orphan Drug Designation For Gastric Cancer Drug

Mersana Therapeutics, Inc. (NASDAQ: MRSN) received orphan drug designation from the U.S. Food and Drug Administration (FDA) for its drug candidate XMT-2056 or the treatment of gastric cancer. The company is planning to start a clinical study evaluating XMT-2056 for gastric and other cancers.

Benzinga · May 19, 2022